FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy

Sept 23 (Reuters) – A panel of outside experts advising the US FDA backed the safety of Grail's blood-based cancer detection test, Galleri, on Wednesday, though members were divided on the evidence

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)